VIATRIS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VIATRIS INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $700.00K, a 0.00% change year-over-year.
- VIATRIS INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $500.00K, a 16.67% decline year-over-year.
- VIATRIS INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $600.00K, a 0.00% change year-over-year.
- VIATRIS INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $700.00K, a 0.00% change year-over-year.
- VIATRIS INC. stock issued during period, value, new issues for fiscal 2023 was $3.10M, a 6.06% decline from fiscal 2022.
- VIATRIS INC. stock issued during period, value, new issues for fiscal 2022 was $3.30M.
- VIATRIS INC. stock issued during period, value, new issues for fiscal 2020 was $0.00.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-07 | |
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $700.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-07 | |
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-06 | $2.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $700.00K 10-Q · filed 2025-08-07 | $2.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-08 | $2.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $700.00K 10-Q · filed 2024-11-07 | $3.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-08 | $4.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-09 | $4.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.80M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $700.00K 10-Q · filed 2023-08-07 | |
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |